ArticleEuropean journal of nuclear medicine and molecular imaging2022
[
Article in European journal of nuclear medicine and molecular imaging, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 46 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
46 citing papers in PubMed, 2 syntheses or guidelines pooled it, 60 citations in OpenAlex.
- Investigating the significance of SPECT/CT-SUV for monitoringBMC medical imaging · 2025Pooled it
- Joint EANM/SNMMI procedure guideline for the use ofEuropean journal of nuclear medicine and molecular imaging · 2023Guideline
- Artificial Intelligence Across the Cancer Theranostics Workflow: Critical Appraisal of Current Evidence and Future Clinical Translation.Molecular imaging and biology · 2026Review
- Applications of artificial intelligence in nuclear medicine.Zeitschrift fur medizinische Physik · 2026Review
- State-of-the-art and future developments in dosimetry for SSTR- and PSMA-targeting radioligand therapies.Zeitschrift fur medizinische Physik · 2026Review
- Impact of posture change on patient-specific absorbed dose estimation in nuclear medicine.Annals of nuclear medicine · 2026Article
- Preliminary feasibility of pre-treatment F-18-PSMA-1007 PET/CT in dose prediction for Lu-177-PSMA-I&T therapy.Acta oncologica (Stockholm, Sweden) · 2026Article
- Inter-center variability of dosimetry methodology and the impact on reported absorbed dose for [European journal of nuclear medicine and molecular imaging · 2026Article
- Limitations in diagnostics and quantification of small lesions with low uptake in the clinical context of prostateEJNMMI physics · 2026Article
- PET-based risk stratification for adverse events under [European journal of nuclear medicine and molecular imaging · 2026Article
- CXCR4-targeted PET imaging of glioblastoma using [EJNMMI radiopharmacy and chemistry · 2026Article
- Prognostic value of whole-body tumor SUV dispersion on baseline PSMA PET prior to PSMA radioligand therapy.Annals of nuclear medicine · 2026Article
- Towards practical radiopharmaceutical treatment planning: a review of dosimetry simplification techniques.Theranostics · 2026Review
- FDG/PSMA discordance in [Frontiers in oncology · 2026Review
- A Trifunctional, Rare-Earth Theranostic Chelator Platform to Enable Diagnostic Nuclear Imaging, Surgical Resection, and Radiotherapy.Journal of the American Chemical Society · 2025Article
- Development and In Vitro Evaluation of [International journal of molecular sciences · 2025Article
- Long Axial Field-of-view PET: A New Era of Quantitative PET Imaging for Theranostic Applications in Clinic.PET clinics · 2025Review
- The tumour sink effect onCancer imaging : the official publication of the International Cancer Imaging Society · 2025Observational
- Radionuclides Landscape in Prostate Cancer Theranostics.International journal of molecular sciences · 2025Review
- CanJournal of nuclear medicine : official publication, Society of Nuclear Medicine · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionPatient eligibility for [
methodsTen patients with low-volume hormone-sensitive prostate cancer received a pre-therapeutic [
resultsPET/SPECT absorbed dose ratio was 1.01 ± 0.21, 1.10 ± 0.15, 1.20 ± 0.34, and 1.11 ± 0.29 for kidneys (using a 2.2 scaling factor), liver, submandibular, and parotid glands, respectively. While a large inter-patient variation in lesion kinetics was observed, PET/SPECT absorbed dose ratio was 1.3 ± 0.7 (range: 0.4-2.7, correlation coefficient r = 0.69, p < 0.01).
conclusionA single time point [
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.